The global sleep apnea devices market size was estimated at around USD $4.30 billion in 2022 and it is projected to hit around USD $7.92 billion by 2032, growing at a CAGR of 6.30% from 2023 to 2032.
Report Scope of The Sleep Apnea Devices Market:
|Market Size In 2022||USD $4.30 Billion|
|Revenue Forecast By 2032||USD $7.92 Billion|
|Growth Rate From 2023 to 2032||6.30%|
|Segments Covered||Product Type|
|Market Analysis (Terms Used)||Revenue In USD Million/Billion And CAGR From 2023 To 2032|
|Regional Scope||North America; Europe; Asia Pacific; Latin America; MEA|
|Key Companies Profiled||ResMed; Phillips Respironics; Fisher & Paykel Healthcare Limited; Curative Medical, Inc.; Invacare Corporation; Somnetics International, Inc.; BMC Medical Co., Ltd.; Natus Medical Incorporated; SOMNOmedics GmbH; Compumedics Limited; Itamar Medical Ltd.; Nihon Kohden Corporation|
Obstructive Sleep Apnea (OSA) is a sleep disorder with irregular breathing reducing oxygen supply to the brain. As per the Chest Physician estimates in 2019, approximately 170 million individuals in the U.S. were diagnosed with OSA. According to the European Respiratory Journal in 2018, the estimated prevalence of OSA in 50 European countries was approximately 175 million. Changing lifestyle, a growing geriatric population, and the rising prevalence of chronic disorders is contributing to the growing incidence of OSA. The growing prevalence of apnea in the geriatric population remains under diagnosis of OSA due to a lack of awareness amongst individuals and poor presentation of OSA. The increasing life expectancy amongst the global geriatric population is expected to contribute to the growing prevalence of sleep disorders.
As per the United Nations World Population Ageing Report in 2019, approximately 703 million individuals across the globe are aged 65 years and above. Similarly, as per the World Health Organization (WHO) estimates the proportion of the world’s geriatric population is expected to double from 12% in 2015 to 22% in 2050 and is expected to reach 2 billion individuals.
The occurrence of OSA in the geriatric population is growing and it affects 13.0% to 32.0% of the global geriatric population in 2020. Therefore, the growing geriatric population and rising awareness levels are anticipated to boost the adoption of sleep apnea devices. Changing lifestyles coupled with the growing prevalence of hypertension and obesity is contributing to the growing occurrence of sleep apnea.
As per CDC estimates in 2017 - 2018, the prevalence of obesity in the U.S. was 42.4.0% and as per CDC estimates in 2019, the prevalence of hypertension in the U.S. was 47.0% accounting for 116 million individuals. According to PubMed estimates in 2019, the prevalence of hypertension was recorded at 55%. As per Eurostat estimates in 2019, 36% of the European population is pre-obese and 17% of the European population is obese.
As per studies undertaken by Mayo Clinic, males are 2-3 times more susceptible to sleep apnea than females. the National Library of Medicine article published in August 2017 on the prevalence of OSA stated that OSA occurrence is found to be higher in men (90%) as compared to women (78%). The prevalence of OSA increases with increasing age and is expected to rise rapidly over the forthcoming years. The increasing patient pool diagnosed with OSA is anticipated to drive the demand for sleep apnea treatment devices.
The growing incidence rate of chronic conditions is expected to increase the burden of OSA. Comorbidities such as diabetes, hypertension, cardiovascular diseases, and obesity are commonly associated with OSA. Some of the characteristics of OSA are frequent episodes of apnea & hypopnea, the collapse of the airway, and irregularities in breathing which result in adverse effects on the body. As per studies, 73% of patients suffer from Sleep-disordered Breathing (SDB) who have been diagnosed with stable heart failure episodes.
Global Sleep Apnea Devices Market Segmentation: